Use of R-mini-CHP in combination with polatuzumab vedotin (pola-R-mini-CHP) as the primary treatment in ≥80-year-old cases with diffuse large B-cell lymphoma.

J Clin Exp Hematop · 2023 · PMC10861370 · PMID 38148017

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

18 In the POLARIX study, a subgroup analysis showed a trend towards better PFS in subjects who were Asian, and those with the ABC type and DE type. 17 Pola-R-CHP is now regarded as one of the standard regimen. 5 , 11 , 12 However, cases aged ≥81 years were excluded from the aforementioned clinical studies, and the efficacy and safety of Pola-R-CHP in this age group remain unknown.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.